An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Glycerol Phenylbutyrate (Ravicti) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.
The manufacturer’s base-case results (reported from the probabilistic sensitivity analysis [PSA]) are summarized in Table 3. This analysis probabilistically varied survival following HAC events, liver-transplant probabilities among patients with neonatal onset, and costs for both HAC events and urea cycle disorder (UCD) management.
Manufacturer’s Results for Patients with Urea Cycle Disorder.
In all four of the subgroups, GPB is suggested to become the most cost-effective option only at values far above an indicative cost per QALY threshold of $50,000. In three of the four subgroups, this figure exceeds $1 million per QALY, with the two subgroups comparing GPB with NaPBA having incremental cost-utility ratios (ICURs) exceeding $5 million per QALY.
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Your browsing activity is empty.
Activity recording is turned off.
See more...
